Eupraxia Pharmaceuticals Inc
TSX:EPRX
Eupraxia Pharmaceuticals Inc
TSX:EPRX
Price:
3.84 CAD
3.23%
Updated:
May 3, 2024
Eupraxia Pharmaceuticals Inc
Net Income (Common)
|
Eupraxia Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Comparables:
ZYME
RPTX
FUSN
AUPH
EDT
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Net Income (Common)
-CA$28.2m
|
CAGR 3-Years
-92%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Zymeworks Inc
NYSE:ZYME
|
Net Income (Common)
-$118.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Net Income (Common)
-$93.8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Net Income (Common)
-$94.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Net Income (Common)
-$78m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-40%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Net Income (Common)
-CA$15.7m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-3%
|
See Also
What is Eupraxia Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-28.2m
CAD
-28.2m
CAD
Based on the financial report for Dec 31, 2023, Eupraxia Pharmaceuticals Inc's Net Income (Common) amounts to -28.2m CAD.
What is Eupraxia Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-16%
-16%
Over the last year, the Net Income (Common) growth was -21%. The average annual Net Income (Common) growth rates for Eupraxia Pharmaceuticals Inc have been -92% over the past three years , -16% over the past five years .
You don't have any saved screeners yet
